Efficacy of LASIK Versus PRK in Asians With Mild and Moderate Myopia
Launched by SINGAPORE NATIONAL EYE CENTRE · Jul 3, 2006
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
This study is a prospective, randomized, clinical trial comparing the efficacy, predictability, stability and safety of LASIK versus PRK in a volunteer group of myopic military servicemen recruited from the Singapore Armed Forces. 132 subjects who were eligible for the study were randomized to undergo either LASIK or PRK in both eyes in a 2:1 ratio. 45 subjects (90 eyes) underwent PRK and 87 subjects (174 eyes) underwent LASIK.
An additional 59 subject underwent a non-randomised arm of the study and underwent PRK.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female subjects were eligible for the study if they were 18 years old or older and had given informed consent; had stable myopia ranging from -2.00 to -5.00D of spherical equivalent myopia, but less than 2.00D of refractive astigmatism as determined by manifest refraction for at least 6 months; a best corrected visual acuity of at least 20/20 and a stable keratometry after not wearing soft contact lenses for at least 2 weeks and hard lenses for at least 3 weeks. Study subjects were required to have a minimum cornea thickness of at least 460um as measured by Orbscan pachymetry.
- Exclusion Criteria:
- • Subjects were excluded if they had corneal or anterior segment pathology, or myopic peripheral retinal degeneration or myopic macular degeneration; clinical signs of progressive or unstable myopia or keratoconus or were keratoconus suspects; were one-eyed patients; had undergone previous ocular surgery; had a history of herpes zoster ophthalmicus or herpes simplex keratitis; had a history of steroid-responsive rise in intraocular pressure or had a preoperative intraocular pressure of more than 21 mmHg in either eye; had diabetes mellitus, auto-immune disease, severe dry eye, connective tissue disease or significant atopy; on chronic systemic corticosteroid or immunosuppressive therapy; had a cornea thickness which would have resulted in less than 250 microns of remaining posterior corneal thickness below the flap postoperatively or had a central corneal endothelial cell count of less than 1500 cells/mm2 in either eye
About Singapore National Eye Centre
The Singapore National Eye Centre (SNEC) is a premier institution dedicated to advancing ophthalmic care through innovative research and clinical excellence. As a leading clinical trial sponsor, SNEC focuses on improving the diagnosis and treatment of a wide range of eye conditions, leveraging cutting-edge technologies and methodologies. Committed to enhancing patient outcomes, SNEC collaborates with a network of healthcare professionals and researchers to conduct rigorous clinical trials that contribute to the global understanding of ocular health. Their comprehensive approach integrates patient care with scientific inquiry, ensuring that advancements in eye care are both evidence-based and aligned with the needs of the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Trial Officials
Donald Tan, FAMS
Principal Investigator
Singapore Eye Research Institute
Benjamin Seet
Principal Investigator
Singapore Armed Forces
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials